These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36882138)

  • 1. Type 2 diabetes complications are associated with liver fibrosis independent of hemoglobin A1c.
    Trivedi HD; Tran Q; Fricker Z; Curry MP; Li JX; Lai M
    Ann Hepatol; 2023; 28(3):101087. PubMed ID: 36882138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninvasive Liver Fibrosis Indices as Indicators of Microvascular and Macrovascular Complications in Type 2 Diabetes.
    Erman H; Boyuk B; Arslan S; Akin S; Keskin Ö
    Metab Syndr Relat Disord; 2024 Oct; 22(8):619-625. PubMed ID: 38836748
    [No Abstract]   [Full Text] [Related]  

  • 3. Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications.
    Ciardullo S; Muraca E; Perra S; Bianconi E; Zerbini F; Oltolini A; Cannistraci R; Parmeggiani P; Manzoni G; Gastaldelli A; Lattuada G; Perseghin G
    BMJ Open Diabetes Res Care; 2020 Feb; 8(1):. PubMed ID: 32049637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between fibrosis-4 score and microvascular complications in patients with type 2 diabetes mellitus.
    Erdogan BT; Tam AA; Baser H; Cuhaci Seyrek FN; Polat SB; Ersoy R; Topaloglu O; Cakir B
    Arab J Gastroenterol; 2024 Aug; 25(3):269-274. PubMed ID: 38719663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrosis Risk in Nonalcoholic Fatty Liver Disease Is Related to Chronic Kidney Disease in Older Type 2 Diabetes Patients.
    Sun Y; Hong L; Huang Z; Wang L; Xiong Y; Zong S; Zhang R; Liu J; Zang S
    J Clin Endocrinol Metab; 2022 Aug; 107(9):e3661-e3669. PubMed ID: 35766414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MASLD, hepatic steatosis and fibrosis are associated with the prevalence of chronic kidney disease and retinopathy in adults with type 1 diabetes mellitus.
    Mantovani A; Morieri ML; Aldigeri R; Palmisano L; Masulli M; Bonomo K; Baroni MG; Cossu E; Cimini FA; Cavallo G; Buzzetti R; Mignogna C; Leonetti F; Bacci S; Trevisan R; Pollis RM; Cas AD; de Kreutzenberg SV; Targher G
    Diabetes Metab; 2024 Jan; 50(1):101497. PubMed ID: 37992857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indices of hepatic steatosis and fibrosis in prediabetes and association with diabetes development in the vitamin D and type 2 diabetes study.
    Corbin KD; Pittas AG; Desouza C; Grdinovac KK; Herzig KH; Kashyap SR; Kim SH; Nelson J; Rasouli N; Vickery EM; Knowler WC; Pratley RE
    J Diabetes Complications; 2023 Jun; 37(6):108475. PubMed ID: 37104979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic steatosis with significant fibrosis is associated with an increased 10-year estimated risk of cardiovascular disease in adults with type 1 diabetes mellitus.
    Mantovani A; Morieri ML; Palmisano L; Masulli M; Cossu E; Baroni MG; Bonomo K; Cimini FA; Cavallo G; Buzzetti R; Mignogna C; Leonetti F; Bacci S; Trevisan R; Pollis RM; Aldigeri R; Cas AD; de Kreutzenberg SV; Targher G
    Cardiovasc Diabetol; 2023 Aug; 22(1):204. PubMed ID: 37563618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective study on the prevalence of MASLD in people with type-2 diabetes in the community. Cost effectiveness of screening strategies.
    Forlano R; Stanic T; Jayawardana S; Mullish BH; Yee M; Mossialos E; Goldin R; Petta S; Tsochatzis E; Thursz M; Manousou P
    Liver Int; 2024 Jan; 44(1):61-71. PubMed ID: 37718933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-alcoholic fatty liver disease and incidence of microvascular complications of diabetes in patients with type 2 diabetes: a prospective cohort study.
    Deravi N; Dehghani Firouzabadi F; Moosaie F; Asadigandomani H; Arab Bafrani M; Yoosefi N; Poopak A; Dehghani Firouzabadi M; Poudineh M; Rabizadeh S; Kamel I; Nakhjavani M; Esteghamati A
    Front Endocrinol (Lausanne); 2023; 14():1147458. PubMed ID: 37342261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of glycated hemoglobin with the risk of advanced fibrosis in non-alcoholic fatty liver disease patients without diabetes.
    Yu C; Wang L; Xue H; Lin H; Li Y; Chan SO
    Clin Res Hepatol Gastroenterol; 2019 Feb; 43(1):58-66. PubMed ID: 30274911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation model of fibrosis-8 index score to predict significant fibrosis among patients with nonalcoholic fatty liver disease.
    Prasoppokakorn T; Chan WK; Wong VW; Pitisuttithum P; Mahadeva S; Nik Mustapha NR; Wong GL; Leung HH; Sripongpun P; Treeprasertsuk S
    World J Gastroenterol; 2022 Apr; 28(15):1563-1573. PubMed ID: 35582126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study.
    Park J; Kim G; Kim BS; Han KD; Kwon SY; Park SH; Lee YB; Jin SM; Kim JH
    Cardiovasc Diabetol; 2022 Apr; 21(1):53. PubMed ID: 35429980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver fibrosis is independently associated with diabetic peripheral neuropathy in type 2 diabetes mellitus.
    Huang J; Li R; Liu N; Yi N; Zheng H; Zhang Q; Zhou L; Zhou L; Hu R; Lu B
    J Diabetes Investig; 2021 Nov; 12(11):2019-2027. PubMed ID: 33943028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypertension and diabetes mellitus are associated with high FIB-4 index in a health checkup examination cohort without known liver disease.
    Sato S; Kawai H; Sato S; Iwasaki H; Omori M; Kita Y; Ikeda Y; Awatsu T; Murata A; Taniguchi G; Shimada Y; Genda T
    BMC Gastroenterol; 2022 Nov; 22(1):478. PubMed ID: 36411436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of glycated hemoglobin with non-alcoholic fatty liver disease patients and the severity of liver steatosis and fibrosis measured by transient elastography in adults without diabetes.
    Xie Y; Kong W; Wang X; Wu Z
    BMC Endocr Disord; 2022 Aug; 22(1):220. PubMed ID: 36045348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-alcoholic fatty liver disease (NAFLD) and significant hepatic fibrosis defined by non-invasive assessment in patients with type 2 diabetes.
    Sobhonslidsuk A; Pulsombat A; Kaewdoung P; Petraksa S
    Asian Pac J Cancer Prev; 2015; 16(5):1789-94. PubMed ID: 25773826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of liver fibrosis and steatosis markers in patients with type 2 diabetes after metformin treatment for 2 years.
    Lee HW; Lee JS; Kim BK; Park JY; Kim DY; Ahn SH; Kim SU
    J Diabetes Complications; 2021 Jan; 35(1):107747. PubMed ID: 33616043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of combined tobacco use and type 2 diabetes mellitus on prevalent fibrosis in patients with MASLD.
    Balogun O; Wang JY; Shaikh ES; Liu K; Stoyanova S; Memel ZN; Schultz H; Mun L; Bertman J; Rogen CA; Ibrahim MK; Berschback M; Uche-Anya E; Wilechansky R; Simon TG; Corey KE
    Hepatol Commun; 2023 Nov; 7(11):. PubMed ID: 37889558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
    Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
    Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.